site logo

Arena, completing its turnaround, sells to Pfizer for nearly $7 billion

The San Diego biotech rebounded from a disappointing obesity drug launch to develop a portfolio of inflammation drugs that caught Pfizer’s attention.

Dan Kitwood via Getty Images